Reporting owner · CIK 0002027261

Garfield Alastair

SEC Form 4 history for the last 180 days across 1 company, 4 transactions and 1 filing.

CSOChief Scientific OfficerRHYTHM PHARMACEUTICALS, INC.
Open-market transaction mix0% buys0 buys · 4 sales

Period: Last 180 days

Trade dates in this period: Aug 13, 2026 – Aug 13, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$913k4 sales
Net value−$913kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Garfield Alastair transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
RYTMRHYTHM PHARMACEUTICALS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$95.3kView disclosure →
RYTMRHYTHM PHARMACEUTICALS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$402kView disclosure →
RYTMRHYTHM PHARMACEUTICALS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$182kView disclosure →
RYTMRHYTHM PHARMACEUTICALS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$233kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at RHYTHM PHARMACEUTICALS, INC. on Aug 13, 2026 valued at $95,335.04.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202604$0$912,703.13−$912,703.13

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$228k
Median P/S size$208k
Direct4
Indirect0
Aug 13, 2026sale

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

4 observations · Aug 13, 2026 – Aug 13, 2026. Window ends at the latest available report, not today.

Selected observation · Aug 13, 20262,295 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 13, 20268,051Aug 17, 2026View transaction
Aug 13, 20266,495Aug 17, 2026View transaction
Aug 13, 20263,095Aug 17, 2026View transaction
Aug 13, 20262,295Aug 17, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Garfield Alastair Insider Activity FAQ

SEC Form 4 context

Who is Garfield Alastair?

Garfield Alastair is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002027261.

Which companies has Garfield Alastair reported transactions for?

RHYTHM PHARMACEUTICALS, INC.

When was Garfield Alastair's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Garfield Alastair's latest insider sale?

The insider reported a sale at RHYTHM PHARMACEUTICALS, INC. on Aug 13, 2026 valued at $95,335.04.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.